Trade 122

SELL LLY

0.11803356 shares at $1,194.00 on 2026-08-26

Reasoning

Take-profit band trigger: LLY position is +17% from cost vs. thesis #36's stated 10-15% take-profit band. Fresh sector headwind (White House drug-pricing deals, macro signal #1966) sold pharma hard (LLY -3.2% today). Partial 40% exit into strength retains core as defensive ballast. This is band-discipline enforcement, not momentum panic. No prior playbook LLY action to reverse — first-touch band trigger with independent policy overhang as secondary confirmation.

Thesis

LLY defensive pharma long — GLP-1/incretin franchise leader (Zepbound/Mounjaro) plus deep cardiometabolic pipeline; held as rate-shielded defensive-growth ballast. Partial profit-take was executed Aug 26 at the 10-15%+ band; remaining core managed on trail. FRESH POSITIVE CATALYSTS (Sep 22): LLY received full FDA approval for Inluriyo in ESR1-mutated breast cancer (regulatory/bullish), and the CEO said its oral GLP-1 Foundayo is winning ~1/3 of new oral GLP-1 scripts (product/bullish/high) — validating the oral-incretin land-grab against competitors. Offsetting overhang persists: renewed drug-pricing/Medicare scrutiny (most-favored-nation, CMS lab payment cuts). Net: franchise fundamentals strengthening; hold the retained core as ballast on trail, do not re-trim on the same band. (long, medium confidence)

Outcome

7-day: +3.81% · 30-day: +3.26%

Cited evidence

News

Macro